BCAL Diagnostics Limited

ASX (AUD): BCAL Diagnostics Limited (BDX)

Last Price

0.077

Today's Change

-0.009 (10.46%)

Day's Change

0.077 - 0.085

Trading Volume

156,026

Profile
BDX

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Shane Ryan M.B.A. Mr. Shane Ryan M.B.A.

Full Time Employees:  0 0

IPO Date:  2021-07-21 2021-07-21

CIK: 

ISIN:  AU0000160921 AU0000160921

CUSIP: 

Beta:  0.76 0.76

Last Dividend:  0.00 0.00

Dcf Diff:  0.11 0.11

Dcf:  0.02 0.02

Description

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Address

50 Clarence Street,
Sydney, NSW 2000, AU

61 2 9078 7671

http://www.bcaldiagnostics.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment